TG Therapeutics Inc

XNAS:TGTX

33.34

-0.16 (-0.46%)

7:52:20 PM EDT: $33.40 +0.07 (+0.20%)

Market Cap (Intraday)	5.26B
Current PE	87.08
Forward PE	44.45
2yr Forward PE	17.92

See more stats

Estimates Current Quarter

Revenue	$151.54 Million
Adjusted EPS	$0.22

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

TG Therapeutics Inc Stock, XNAS:TGTX

3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560

United States of America

Phone: +1.212.554.4484

Number of Employees: 338

http://www.tgtherapeutics.com

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.